Hypertrophic Cardiomyopathy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports

DelveInsight's "Hypertrophic Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hypertrophic Cardiomyopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypertrophic Cardiomyopathy Market Forecast
https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Hypertrophic Cardiomyopathy Market Report:
• The Hypertrophic Cardiomyopathy market size was valued ~USD 646 million in 2023 and is anticipated to grow with a significant CAGR of 20% during the study period (2020-2034).
• In September 2025, Specialty cardiovascular biopharmaceutical company Cytokinetics presented the primary results of its Phase III MAPLE-HCM trial at the European Society of Cardiology Congress 2025 in Madrid, while simultaneously publishing the findings in the New England Journal of Medicine. The trial showed that aficamten was superior to metoprolol in treating patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
• In September 2025, A recent analysis published in The New England Journal of Medicine indicates that mavacamten does not provide significant benefits for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). Marketed by Bristol Myers Squibb as Camzyos, mavacamten was approved by the U.S. FDA in 2022 for treating symptomatic obstructive HCM. Currently, there are no FDA-approved therapies for nonobstructive HCM.
• In April 2025, Bristol Myers Squibb's (BMS) Phase III ODYSSEY-HCM trial testing Camzyos (mavacamten) in non-obstructive hypertrophic cardiomyopathy (nHCM) patients did not meet its two primary endpoints. After 48 weeks of treatment, the cardiac myosin inhibitor failed to show a meaningful benefit over placebo in enhancing either the Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-23 CSS) or peak oxygen consumption (pVO2). The study, which was randomized, double-blind, and placebo-controlled, enrolled 580 adults with symptomatic nHCM categorized as NYHA class II or III.
• In April 2025, Interim findings from the Phase Ib/2 MYPEAK-1 trial (NCT05836259) revealed that three patients with severe heart disease showed improved physical activity after receiving a single dose of Tenaya Therapeutics' gene therapy, TN-201. Presented at a late-breaking session during the 2025 American College of Cardiology (ACC) conference, the data indicated that TN-201, designed to treat hypertrophic cardiomyopathy (HCM), was well tolerated and demonstrated a favorable safety profile in the initial three patients enrolled in the first cohort.
• In September 2024, Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a prominent biopharmaceutical company focused on muscle diseases, has announced top-line data for EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomyopathy (HCM). EDG-7500 is an innovative oral, selective cardiac sarcomere modulator designed to reduce early contraction velocity and improve impaired cardiac relaxation associated with HCM.
• In April 2024, Imbria Pharmaceuticals, Inc., a clinical-stage cardiometabolic company focused on developing innovative therapies to enhance patient symptoms and functional capacity by improving cellular energetics, announced that findings from the Phase 2 IMPROVE-HCM clinical trial investigating ninerafaxstat in patients with symptomatic nHCM were unveiled during a late-breaking clinical trial session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.24) and published in the Journal of the American College of Cardiology (JACC).
• In 2023, the United States held the largest market share for Hypertrophic Cardiomyopathy, representing about 78% of the total market size across the 7MM, surpassing other key markets such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2023, Germany had the largest Hypertrophic Cardiomyopathy market size among European countries, reaching approximately USD 33 million, whereas Spain had the smallest market size, around USD 23 million.
• In 2023, the market size for Hypertrophic Cardiomyopathy in Japan was approximately USD 5 million, representing 1% of the total 7MM market.
• According to DelveInsight's analysis, the estimated total number of prevalent cases of Hypertrophic Cardiomyopathy in the 7MM was approximately 1,079,000 in 2023.
• In 2023, the United States had the highest number of diagnosed prevalent cases of Hypertrophic Cardiomyopathy, estimated at around 118,000, with expectations of growth in the future.
• In 2023, Germany had the highest number of diagnosed prevalent cases of Hypertrophic Cardiomyopathy among European countries, with approximately 32,000 cases, followed by France with around 25,000. Spain had the lowest diagnosed prevalence, with about 19,000 cases.
• In 2023, Japan had around 4,000 diagnosed prevalent cases of Hypertrophic Cardiomyopathy, representing approximately 2% of the total cases across the 7MM.
• In 2023, the United States saw a higher prevalence of diagnosed Hypertrophic Cardiomyopathy cases in males (~57%) compared to females (~43%), which can be attributed to factors like hormonal differences, physiological variations, lifestyle, and occupational influences.
• In the UK, in 2023, Obstructive hypertrophic cardiomyopathy had the highest number of cases, with approximately 16,000, while Non-obstructive hypertrophic cardiomyopathy had the fewest, with around 8,000 cases.
• Key Hypertrophic Cardiomyopathy Companies: Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others
• Key Hypertrophic Cardiomyopathy Therapies: EDG-7500, Sotagliflozin, HRS-1893, Aficamten, RP-A501, Mavacamten, MYK-224, LCZ696, Ranolazine, CK-3773274, IMB-1018972, MYK-461, TN-201, LCZ696, and others
• The Hypertrophic Cardiomyopathy epidemiology based on gender analyzed males are more affected by Hypertrophic Cardiomyopathy than females.
• The Hypertrophic Cardiomyopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypertrophic Cardiomyopathy pipeline products will significantly revolutionize the Hypertrophic Cardiomyopathy market dynamics.

Hypertrophic Cardiomyopathy Overview
Hypertrophic Cardiomyopathy (HCM) is a genetic heart condition characterized by abnormal thickening of the heart muscle, particularly the left ventricle. This thickening can obstruct blood flow and lead to symptoms like chest pain, shortness of breath, dizziness, and irregular heartbeats. While some cases are asymptomatic, treatment options include medications, lifestyle changes, and surgery.

Get a Free sample for the Hypertrophic Cardiomyopathy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hypertrophic Cardiomyopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hypertrophic Cardiomyopathy Epidemiology Segmentation:
The Hypertrophic Cardiomyopathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Hypertrophic Cardiomyopathy
• Prevalent Cases of Hypertrophic Cardiomyopathy by severity
• Gender-specific Prevalence of Hypertrophic Cardiomyopathy
• Diagnosed Cases of Episodic and Chronic Hypertrophic Cardiomyopathy

Download the report to understand which factors are driving Hypertrophic Cardiomyopathy epidemiology trends @ Hypertrophic Cardiomyopathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hypertrophic Cardiomyopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypertrophic Cardiomyopathy market or expected to get launched during the study period. The analysis covers Hypertrophic Cardiomyopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hypertrophic Cardiomyopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypertrophic Cardiomyopathy Therapies and Key Companies
• EDG-7500: Edgewise Therapeutics, Inc.
• Sotagliflozin: Lexicon Pharmaceuticals
• HRS-1893: Shandong Suncadia Medicine
• Aficamten: Ji Xing Pharmaceuticals
• RP-A501: Rocket Pharmaceuticals
• Mavacamten: Bristol-Myers Squibb
• MYK-224: Bristol-Myers Squibb
• LCZ696: Novartis
• Ranolazine: Gilead Sciences
• CK-3773274: Cytokinetics
• IMB-1018972: Imbria Pharmaceuticals
• MYK-461: MyoKardia, Inc.
• Aficamten: Cytokinetics
• TN-201: Tenaya Therapeutics
• LCZ696: Novartis

Discover more about therapies set to grab major Hypertrophic Cardiomyopathy market share @ Hypertrophic Cardiomyopathy Treatment Landscape
https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hypertrophic Cardiomyopathy Market Drivers
• Genetic diagnosis
• Robust Hypertrophic Cardiomyopathy pipeline
• Evolution of surgical techniques
• Increasing number of cases

Hypertrophic Cardiomyopathy Market Barriers
• Under diagnosis
• Missing causal genes
• Knowledge gaps

Scope of the Hypertrophic Cardiomyopathy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hypertrophic Cardiomyopathy Companies: Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others
• Key Hypertrophic Cardiomyopathy Therapies: EDG-7500, Sotagliflozin, HRS-1893, Aficamten, RP-A501, Mavacamten, MYK-224, LCZ696, Ranolazine, CK-3773274, IMB-1018972, MYK-461, TN-201, LCZ696, and others
• Hypertrophic Cardiomyopathy Therapeutic Assessment: Hypertrophic Cardiomyopathy current marketed and Hypertrophic Cardiomyopathy emerging therapies
• Hypertrophic Cardiomyopathy Market Dynamics: Hypertrophic Cardiomyopathy market drivers and Hypertrophic Cardiomyopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hypertrophic Cardiomyopathy Unmet Needs, KOL's views, Analyst's views, Hypertrophic Cardiomyopathy Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.